
Network News

Braunschweig, January 29th, 2025 – YUMAB GmbH, a German biotechnology company specializing in contract research for therapeutic antibodies, announces its collaboration with InSCREENeX GmbH to establish a novel technology for antibody development. As part of the funded project “Mammalian Display,” the two Braunschweig-based companies are developing a platform that enables the screening of antibody libraries […]
read more
New Member: Welcome in our cluster to Menarini Biotech
Menarini Biotech (MBH) is a leading CDMO specializing in Process Development and GMP manufacturing across various therapeutic areas. With a mission to be a reliable, agile, and innovative partner, MBH empowers its customers to bring life-saving biotherapeutics to patients through expertise in drug development. From lab to production, cutting-edge technology accelerates processes, optimizes yields, and […]
read more
New Member: Welcome in our cluster to GeneTechX
At GeneTechX, they are developing a nutrigenomics platform that combines genetics and nutritional science to create personalized dietary solutions. Leveraging advanced gene-editing technologies like PrimeCRISPR, they investigate the intricate relationships between genes, diet, and health outcomes. By identifying genetic variations that affect nutrient metabolism, GeneTechX delivers tailored nutrition strategies to enhance health and prevent disease, […]
read more
New Member: Welcome in our cluster to Akribion Therapeutics GmbH
Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Its G-dase® E nuclease has the ability to kill cells by shredding DNA and RNA, but only if there is a highly specific match between the guide RNA and an intracellular RNA sequence. This ensures that only the targeted cells are affected, […]
read more
New weapons against viruses
Dr. Petr Chlanda, virologist and research group leader at the Heidelberg Medical Faculty of Heidelberg University, has been awarded more than 720,000 euros in funding from the European Union for his research into new therapies against viruses. His work is part of the interdisciplinary, international DEFENDER project, which is developing innovative approaches to combat emerging […]
read more
BioChatter: making large language models accessible for biomedical research
Introducing an open-source large language model (LLM) framework designed for custom biomedical research Summary Large language models (LLMs) have transformed how many of us work, from supporting content creation and coding to improving search engines. However, the lack of transparency, reproducibility, and customisation of LLMs remains a challenge that restricts their widespread use in biomedical […]
read more
New approach to fighting cancer: energy trap for tumor cells
Glycolysis is an important sugar degradation pathway that cancer cells in particular depend on. Scientists at the German Cancer Research Center (DKFZ) have now shown that liver cancer cells in mice and humans depend on a key enzyme of glycolysis, Aldolase A. When it is switched off, glycolysis reverses from an energy-producing to an energy-consuming […]
read more
New Publication from AbbVie and Sciomics: Exploration of Novel Biomarkers for Neurodegenerative Diseases Using Proteomic Analysis and Ligand-Binding Assays
Kenzelmann A, Boch C, Schmidt R, Richter M, Schulz M. Exploration of Novel Biomarkers for Neurodegenerative Diseases Using Proteomic Analysis and Ligand-Binding Assays. Biomedicines. 2024 Dec 9;12(12):2794. doi: 10.3390/biomedicines12122794. PMID: 39767701; PMCID: PMC11673003. Abstract Background/objectives: Neurodegenerative diseases are a major cause of morbidity and mortality worldwide, and their public health burden continues to increase. There is […]
read more
New Publication: Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1-HER3 signaling
Würth, R., Donato, E., Michel, L.L. et al. Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1–HER3 signaling. Nat Cancer (2025). https://doi.org/10.1038/s43018-024-00882-2 Abstract Circulating tumor cells (CTCs) drive metastasis, the leading cause of death in individuals with breast cancer. Due to their low abundance in the circulation, robust CTC expansion protocols are urgently needed to effectively […]
read more